ORAL DELIVERY of testosterone

The main challenge with the oral delivery of Testosterone is the high first pass metabolism that degrades the molecule in the liver, limiting it bioavailability. Testosterone is also poorly water soluble and has proven to be extremely difficult to administer in a safe and efficacious manner.

Utilizing TesoRx's novel drug delivery technology, Testosterone Undecanoate (TU) is reformulated as a solid neoliposomal powder that is encased in an enteric coated capsule. The capsule bypasses gastric breakdown and releases the capsule contents in the small intestine. Once released, neoliposomal TU complexes form spontaneously and are absorbed directly into the GI lymphatic system. TU is directly released into the blood stream, bypassing 1st pass in the liver, resulting in enhanced bioavailability of the drug.

Read more about TesoRx’s oral Testosterone products for Hypogonadism in men and Constitutional Delay in Growth and Puberty for boys.


targeted INTRACAVITARY CHEMOTHERAPY DELIVERY

LIPAC Oncology, a subsidiary of TesoRx Pharma, is employing LiPax, its proprietary neoliposomal intracavitary paclitaxel drug delivery platform, to enhance and reformulate proven cancer drugs into more effective treatments. LiPax, a locally delivered formulation of paclitaxel, is being developed for the intravesical treatment of non-muscle invasive bladder cancer (NMIBC). LIPAC’s growing pipeline targets areas of great unmet need in Bladder Cancer, Upper Tract Urothelial Carcinoma, Stage II/III Ovarian Cancer, Intraperitoneal Carcinoma and Mesothelioma/Malignant Pleural Effusion.

Chemotherapy agents are sometimes delivered intravesically (direct instillation into the bladder) or intraperitoneally (into the abdominal cavity) during or following cancer surgery to improve patient outcomes. These agents are not approved for this use and have limitations in efficacy, formulation, and in some cases supply.

Paclitaxel, an agent known to be highly active in systemic application for urothelial carcinomas, is lipophilic and not solubilized in the acidic environment of the bladder. Paclitaxel has not been formulated or approved to be used intravesically in its current formulation. By utilizing LIPAC’s advanced drug delivery platform to enhance permeation and solubility, LiPax overcomes these barriers and represents a breakthrough in the intravesical delivery of paclitaxel. LIPAC has conducted preclinical and clinical studies which demonstrated the superior efficacy of this approach.